BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38102902)

  • 21. Comparison of dosimetric parameters and acute toxicity after whole-pelvic vs prostate-only volumetric-modulated arc therapy with daily image guidance for prostate cancer.
    Ishii K; Ogino R; Hosokawa Y; Fujioka C; Okada W; Nakahara R; Kawamorita R; Tada T; Hayashi Y; Nakajima T
    Br J Radiol; 2016 Jun; 89(1062):20150930. PubMed ID: 26959612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synchronous prostate and rectal adenocarcinomas irradiation utilising volumetric modulated arc therapy.
    Ng SP; Tran T; Moloney P; Sale C; Mathlum M; Ong G; Lynch R
    J Med Radiat Sci; 2015 Dec; 62(4):286-91. PubMed ID: 27512575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature.
    Budäus L; Bolla M; Bossi A; Cozzarini C; Crook J; Widmark A; Wiegel T
    Eur Urol; 2012 Jan; 61(1):112-27. PubMed ID: 22001105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
    Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
    Warde P; Mason M; Ding K; Kirkbride P; Brundage M; Cowan R; Gospodarowicz M; Sanders K; Kostashuk E; Swanson G; Barber J; Hiltz A; Parmar MK; Sathya J; Anderson J; Hayter C; Hetherington J; Sydes MR; Parulekar W;
    Lancet; 2011 Dec; 378(9809):2104-11. PubMed ID: 22056152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer solitary metastasis to anal canal: case report and review of literature.
    Dulskas A; Cereska V; Zurauskas E; Stratilatovas E; Jankevicius F
    BMC Cancer; 2019 Apr; 19(1):374. PubMed ID: 31014272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 11C choline PET guided salvage radiotherapy with volumetric modulation arc therapy and hypofractionation for recurrent prostate cancer after HIFU failure: preliminary results of tolerability and acute toxicity.
    Alongi F; Liardo RL; Iftode C; Lopci E; Villa E; Comito T; Tozzi A; Navarria P; Ascolese AM; Mancosu P; Tomatis S; Bellorofonte C; Arturo C; Scorsetti M
    Technol Cancer Res Treat; 2014 Oct; 13(5):395-401. PubMed ID: 24000995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients.
    Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Munoz F; Rondi N; Morino M; Racca P; Ricardi U
    Br J Radiol; 2016; 89(1060):20150832. PubMed ID: 26838953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.
    Hanks GE; Pajak TF; Porter A; Grignon D; Brereton H; Venkatesan V; Horwitz EM; Lawton C; Rosenthal SA; Sandler HM; Shipley WU;
    J Clin Oncol; 2003 Nov; 21(21):3972-8. PubMed ID: 14581419
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 36. Transitioning from conformal radiotherapy to intensity-modulated radiotherapy after radical prostatectomy: Clinical benefit, oncologic outcomes and incidence of gastrointestinal and urinary toxicities.
    Flores-Balcázar CH; Urías-Arce DM; Bourlon MT; Gabilondo-Navarro F; Pérez-Álvarez SI; Ramos-Prudencio R; Rodríguez-Covarrubias F
    Rep Pract Oncol Radiother; 2020; 25(4):568-573. PubMed ID: 32494230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers: A single institute experience from India.
    Gupta PK; Rastogi N; Maria Das KJ; Kumar S
    J Cancer Res Ther; 2023; 19(2):382-388. PubMed ID: 37006073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) Techniques.
    Tonetto F; Magli A; Moretti E; Guerini AE; Tullio A; Reverberi C; Ceschia T; Spiazzi L; Titone F; Prisco A; Signor MA; Buglione M; De Giorgi G; Trovò M; Triggiani L
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment planning comparison between dynamic wave arc and volumetric modulated arc therapies for prostate-cancer treatment.
    Miura H; Nakao M; Doi Y; Ozawa S; Kenjo M; Nagata Y
    Med Dosim; 2022 Spring; 47(1):48-53. PubMed ID: 34538693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.